XVIVO Perfusion AB
XVIVO Capital Markets Day Presents Strategic Focus Areas for 2022-2026
GOTHENBURG, SE / ACCESSWIRE / September 23, 2021 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)
At the XVIVO Capital Markets Day in Gothenburg, Sweden today, CEO Dag Andersson and other senior executives will focus on the company's strategy to become the world leader in the transplant industry.
XVIVO will present five strategic focus areas for the period 2022 - 2026; Global leader Abdominal (with initial focus on the US); Market leading heart preservation system; Increase penetration of machine perfusion; Secure all-inclusive reimbursement in key geographic areas; and China to become the company's second largest market.
"Strategy is about making choices and about deliberately choosing to be different, and always for us considering our overall vision that nobody should die waiting for a new organ. With our five strategic focus areas we have defined our way forward and the keys to our future success " says Dag Andersson, CEO.
During the Capital Markets Day, financial targets and the actions to reach these targets will be presented. XVIVOs ambition is to reach an EBIT-margin of 20 % and an EBITDA-margin of 30 % during the strategy period. In 2026, Abdominal revenue is expected to be of equal size as Thoracic revenue.
XVIVO will continue to build on its world leading position in lung transplantation and develop the offering to cover all four major organs: lung, heart, kidney and liver.
The Capital Markets Day will be broadcasted live online today, on 23 September 2021, at 13:00 CEST via this link: https://xvivo.creo.se/210923 . A recording of the Capital Markets Day will be available on-demand shortly after the event via the same link.
For further information, please contact:
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-09-23 09:13 CEST.
SOURCE: XVIVO Perfusion AB
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Champions Oncology, Inc.20.10.2021 16:28:12 CEST | Press release
Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus
Physitrack20.10.2021 09:12:03 CEST | Press release
Physitrack PLC – Interim report: December 2020 – August 2021
Re:NewCell AB (publ)19.10.2021 14:17:20 CEST | Press release
Renewcell and Kelheim Fibres Form Collaboration to Establish a European Closed Loop for Fashion
Gungnir Resources Inc.19.10.2021 12:02:20 CEST | Press release
Gungnir Outlines Near-Surface Conductors Outside of Rormyrberget Nickel Resource; Assays Pending for Eight Drill Holes at Lappvattnet
Volcon ePowersports, Inc.18.10.2021 15:40:53 CEST | Press release
Volcon Partners with Tier One Design Firm that Services Jeep, Dodge, Ford, GM, Nissan, and Toyota
XVIVO Perfusion AB18.10.2021 15:17:01 CEST | Press release
Record for a Donor Heart Outside the Body Using Ground-Breaking XVIVO Technology
RepliCel Life Sciences, Inc.18.10.2021 15:09:29 CEST | Press release
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom